New Sleep Drug Passes Early Clinical Test
Insomniacs had statistically significant, dose-related improvement in sleep efficiency over 4 weeks when treated with a new class of sleep aid, results of a placebo-crossover trial showed.
As compared with placebo, the orexin-receptor antagonist suvorexant improved sleep efficiency ranging from 5% to 13% during the first day of treatment and from 5% to 8% after 4 weeks, according to W. Joseph Herring, MD, PhD, of Merck Sharp & Dohme in Whitehouse Station, N.J., and co-authors.
No comments:
Post a Comment